์๋ ์คํฐ๋ณด๊ธ๋ฃจ์ฝ๋ค์ดํธ
์๋ ์คํฐ๋ณด๊ธ๋ฃจ์ฝ๋ค์ดํธ๋ ๊ฐ์ ๋ฆฌ์๋งํธ๋ชจ์ถฉ์ฆ ์น๋ฃ์ ์ฌ์ฉ๋๋ 5๊ฐ ์ํฐ๋ชฌ ํํฉ๋ฌผ์ ๋๋ค. ๋ฏธ๊ตญ์์๋ ์ํ๋์ง ์์ผ๋ฉฐ CDC๋ฅผ ํตํด ๊ณต๊ธ๋ฉ๋๋ค. ์ฌ๊ฐํ ๋ถ์์ฉ์ ์ํ์ด ์์ผ๋ฏ๋ก ์ฃผ์ํด์ ์ฌ์ฉํด์ผ ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : The exact mechanism of action of sodium stibogluconate remains incompletely elucidated. * **Prodrug Hypothesis:** It is widely hypothesized to act as a prodrug, where the pentavalent antimony (SbV) is reduced to the more toxic trivalent antimony (SbIII) within the host macrophage or the parasite itself. * **Bioenergetic Disruption:** It is believed to interfere with the parasite's bioenergetics by reducing **ATP and GTP synthesis** in susceptible *Leishmania* amastigotes, ultimately leading to parasite death.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Treatment of cutaneous leishmaniasis ยท 30-50 mg/kg IV or SC daily ยท IV/SC ยท q24h ยท 3-4 weeks
- Treatment of visceral leishmaniasis ยท 30-50 mg/kg IV or SC q24h ยท IV/SC ยท q24h ยท one month ยท Has severe side effects and may not be obtainable in the USA; allopurinol alone is usually used initially.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Pre-existing cardiac arrhythmias
- Significantly impaired renal function
- Previous serious adverse reaction to a dose of stibogluconate
- Severe renal impairment
- Severe hepatic impairment
์ด์๋ฐ์
- Increased AST levels
- Pain on injection
- Musculoskeletal pain
- Hemolytic anemia
- Leukopenia
- Vomiting
- Diarrhea
- Pancreatitis
- Myocardial injury and arrhythmias
- Renal toxicity
- Shock
- Sudden death
- Thrombophlebitis (with IV administration)
- Nephrotoxicity
- Hepatotoxicity
- Injection site pain
- Lethargy
์ฝ๋ฌผ ์ํธ์์ฉ
- Amphotericin B ยท Increased risk of nephrotoxicity ยท major
- Allopurinol ยท Synergistic antileishmanial effect (often used together clinically) ยท minor
๋ชจ๋ํฐ๋ง
- CBC
- Liver enzymes (especially AST)
- Renal function tests
- ECG (for myocardial injury/arrhythmias)
- Bone marrow cultures for Leishmania
- Clinical efficacy
- Renal function (BUN, Creatinine, SDMA, Urinalysis)
- Hepatic enzymes (ALT, AST, ALP)
- Pancreatic enzymes (cPLI, Lipase)
- ECG (for arrhythmias)
๊ณผ์ฉ๋
In the unlikely event of a parenterally administered overdose, it is suggested to immediately contact an animal poison control center. * **Chelation Therapy:** Potentially, antimony toxicity can be managed by chelating agents such as **dimercaptosuccinic acid (DMSA)** or **d-penicillamine** to enhance excretion.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.